
|Articles|October 8, 2014
- NSCLC (Issue 4)
- Volume 4
- Issue 1
The Implementation of Personalized Medicine for Lung Cancer Patients
Author(s)Vassiliki Papadimitrakopoulou, MD
Vassiliki Papadimitrakopoulou, MD, from the University of Texas MD Anderson Cancer Center, discusses the implementation of personalized medicine for lung cancer patients.
Advertisement
Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the implementation of personalized medicine for lung cancer patients.
Articles in this issue
over 11 years ago
The Benefit of Treating Lung Cancer with Immunotherapyover 11 years ago
The Cancer Genome Atlas Plays Role in Future Therapies for NSCLCover 11 years ago
In Practice: Systemic Treatment for Metastatic NSCLCover 11 years ago
The Importance of Biomarkers for Lung Cancerover 11 years ago
Clinical Trial Profile: The OAK Studyover 11 years ago
Optimizing of Therapeutic Sequencing Being Studied in NSCLCAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















